Skip to content

Monitored Anesthesia Care vs. General Anesthesia for Transcatheter Aortic Valve Replacement

A Randomized Controlled Trial Comparing Monitored Anesthesia Care Versus General Anesthesia With Transesophgeal Echocardiography for Transcatheter Aortic Valve Replacement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04107038
Enrollment
170
Registered
2019-09-27
Start date
2019-11-22
Completion date
2025-08-15
Last updated
2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transcatheter Aortic Valve Replacement

Keywords

Anesthesia, TAVR, Cardiothoracic, Cardiology

Brief summary

This study is being done to evaluate the impact that monitored anesthetic care (MAC) versus general endotracheal anesthesia (GETA) has on hospital length of stay, rate of ICU admission, and procedural mortality for patients undergoing Transcatheter Aortic Valve Replacement (TAVR). Also, the investigators hope to determine if the use of Transesophageal Echocardiography (TEE) during GETA impacts device success. Adult patients undergoing transfemoral approach TAVR for aortic valve stenosis may be eligible candidates for this study.

Interventions

Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.

PROCEDUREMonitored anesthesia care

Participants receive monitored anesthesia care for their procedure.

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients ≥ 18 years old * Adult patients undergoing transfemoral approach TAVR for aortic valve stenosis * Adult patients who are medically eligible to receive both anesthetics (GA and MAC)

Exclusion criteria

* Inability to speak English * Body Mass Index (BMI) \> 37 kg/m2 * History of difficult airway requiring fiberoptic intubation * Inability to lie flat * Women who are pregnant * Patients who have contraindications to either anesthetic, such as an allergy or history of malignant hyperthermia, will also be excluded from the study. * Inability or unwillingness of subject to give informed consent based on any reason * Patients with any of the following absolute contraindications to TEE: * Perforated Viscus * Esophageal Stricture * Esophageal Tumor * Esophageal Perforation * Esophageal Diverticulum * Active upper GI Bleed

Design outcomes

Primary

MeasureTime frameDescription
Hospital Length of StayUp to 1 monthThe total number of hours that the patient stayed in the hospital will be measured from the Anesthesia Start time until their time of discharge, as recorded in their electronic medical record.
ICU Admission RateUp to 48 hoursThe investigators will determine the ICU admission rate by taking the total number of patients admitted to the ICU and dividing it by the number of cases in each arm of the study, based on MUSC's fast track pathway and our inclusion.
Procedural MortalityUp to 30 daysThe percentage of the study population that died within 30 days of their procedure or during index procedure hospitalization - if the postoperative length of stay is longer than 30 days.

Secondary

MeasureTime frameDescription
Paravalvular RegurgitationFor GETA cases, will be recorded after valve implantation. For all cases, will be recorded from a TTE report that is completed on post-operative day 1 or 2 and at 1 year.Paravalvular regurgitation is a specific type of aortic regurgitation that is determined qualitatively by the echocardiographer. It is defined as the grade of aortic valve regurgitation around the perimeter of the implanted prosthesis. The assigned grade will be classified according to a unifying five-class scheme, at the determination of the cardiologist. Grade of aortic regurgitation is measured as none, mild, moderate, or severe. None is best, severe is worst. For GETA cases, paravalvular regurgitation will be recorded after valve implantation by the anesthesiologist performing TEE, as is routine. For all cases, paravalvular regurgitation will be recorded from a TTE report that is completed on post-operative day 1 or 2 (the 1st post-operative TTE) during routine clinical care, and again by TTE report at 1 year during routine clinical follow-up.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026